Frequently Asked Questions

Discovery proteomics is the unbiased, large-scale identification and quantification of all proteins expressed in a biological sample, typically measuring 8,000+ proteins using high-resolution mass spectrometry.

Unlike targeted panels (such as Western Blots, ELISA, or multiplex arrays) which only measure a pre-selected list of 50 to 200 proteins, discovery proteomics scans the whole proteome. This prevents biological blind spots and allows researchers to discover novel biomarker networks, metabolic pathways, and unexpected drug-resistance mechanism signatures.

Peer-reviewed clinical trial statistics indicate that oncology therapeutic candidates face a staggering 95% failure rate during development, leading to an overall approval rate of just 3.4% (Wong, Siah & Lo, 2019). Furthermore, industry audits show that 90% of clinical drug failures stem from a lack of clinical efficacy (40–50%) or safety/toxicity issues (30%) (Sun et al., 2022).

Global proteomics directly resolves this failure point. By mapping the active proteome of patient-derived cell models (ProteoModels) prior to clinical entrance, Yatiri Bio identifies the specific biomarker signatures that correlate with drug sensitivity. This allows biopharma companies to design clinical trials with highly defined patient selection criteria, increasing the likelihood of therapeutic response.

Phosphoproteomics is the specialized branch of proteomics that isolates and characterizes phosphorylated proteins, a vital post-translational modification (PTM) regulating cellular signaling networks.

Because protein abundance does not always match protein activity, measuring PTMs allows us to chart hyperactive kinase networks, map mechanisms of action for kinase inhibitors, and identify active escape pathways responsible for drug resistance.

ProteoModels represent Yatiri Bio's proprietary database of patient-derived cellular and ex-vivo models characterized by baseline global proteomics.

We cross-reference these models' baseline proteomes and phosphorylation profiles against therapeutic sensitivity screens to discover biomarkers that correlate with oncology drug response, focusing heavily on Acute Myeloid Leukemia (AML) and ovarian cancer.

On August 5, 2025, Yatiri Bio completed the acquisition of San Diego-based NGeneBioAI, Inc. (a Bertis-derived plasma-proteomics innovator) in an undisclosed stock transaction.

This transaction integrated NGeneBioAI's established CLIA-certified (Clinical Laboratory Improvement Amendments) and CAP-certified (College of American Pathologists) laboratory facilities located at 6335 Nancy Ridge Dr. This infrastructure allows Yatiri Bio to convert preclinical research biomarker signatures into validated companion diagnostic assays for clinical trial cohorts.

Dr. Pilgrim Jackson is the Co-Founder & CEO of Yatiri Bio, Inc. and a systems biologist with a PhD from the University of California, Santa Cruz.

He has co-authored several key patents relating to the cereblon (CRBN) pathways and biomarker mechanisms of action, including Google Patent WO2014004990A2 during his scientific tenure at Celgene.